Intravesical Instillation of Hyaluronic Acid (Cystistat) for the Treatment of Category III Prostatitis: A Retrospective Study

Intravesical hyaluronic acid (Cystistat) therapy appears to be clinically effective for CP/CPPS, particularly in pain relief and quality-of-life improvement. Patients with elevated CRP levels and shorter disease duration may benefit more from this treatment. The derived predictive model offers a tool for individualized clinical decision-making. These findings lend indirect support to the "bladder-prostate axis" hypothesis, suggesting that Cystistat may alleviate pelvic pain by restoring bladder mucosal integrity and reducing inflammatory mediator activity. Future prospective randomized controlled trials are needed to validate these findings and further elucidate the underlying mechanisms. Further prospective, large-scale studies are needed to confirm efficacy, especially in OAB-associated subtypes, and refine predictive modeling approaches.